查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933349

全球细菌疫苗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的分析以及未来预测（2026-2034）

Bacterial Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 170 Pages | 商品交期: 请询问到货日

价格

细菌疫苗市场成长因素

受细菌感染发生率上升、疫苗接种计划扩大以及各地区政府大力支持等因素的推动，全球细菌疫苗市场正经历强劲增长。根据 Fortune Business Insights 的数据显示，2025 年全球细菌疫苗市场规模为 296.8 亿美元。预计到 2026 年将达到 325.2 亿美元，到 2034 年将达到 813.5 亿美元，预测期内复合年增长率 (CAGR) 为 12.14%。北美地区凭藉较高的疫苗接种率和先进的医疗基础设施，在 2025 年占市场主导地位，市占率达 40.97%。

细菌疫苗旨在透过刺激免疫系统识别并中和细菌病原体来保护个体免受细菌感染。这些疫苗在预防危及生命的疾病方面发挥关键作用，例如肺炎球菌感染、脑膜炎双球菌感染、白喉、破伤风和百日咳。人们对医疗保健和疫苗接种益处的认识不断提高，并持续推动全球对细菌疫苗的需求。

市场动态

市场驱动因素

全球细菌性疾病发生率的上升是市场成长的主要驱动因素。快速的城市化、人口密度的增加以及国际旅行和移民都促进了细菌感染的传播，从而增加了对有效疫苗接种策略的需求。此外，公众疾病预防意识的提高和国家疫苗接种计划的扩大显着提高了疫苗接种覆盖率，从而支持了市场扩张。

市场限制因子

监管障碍是细菌疫苗市场面临的主要限制因素。 疫苗研发需要漫长的临床试验、严格的监管合规性以及大量的资金投入，研发週期通常长达 10 至 15 年。各国监管要求的差异进一步加剧了全球审批和商业化的复杂性，限制了市场成长。

市场机会

日益严重的抗菌素抗药性 (AMR) 为细菌疫苗市场带来了巨大的机会。接种疫苗可以减少对抗生素的依赖，并有助于遏制抗药性细菌的出现。在全球抗生素抗药性蔓延的背景下，细菌疫苗作为一种预防措施正日益受到重视，从而推动了疫苗研发投资和资金的增加。

市场挑战

细菌的生物复杂性为疫苗研发带来了重大挑战。与病毒不同，细菌拥有多种抗原，这使得识别能够产生持久保护性免疫反应的标靶变得困难。这种复杂性增加了研发成本和风险，可能会限制市场成长。

细菌疫苗市场趋势

影响市场走向的显着趋势之一是耐热细菌疫苗的研发。这类疫苗可在较宽的温度范围内保持稳定，从而降低对冷链物流的依赖。耐热疫苗提供了一种经济高效且实用的解决方案，尤其适用于基础设施有限的新兴经济体。预计在预测期内，冷藏疫苗研发投入的增加和正在进行的临床试验将进一步巩固这一趋势。

细分市场分析

依类型划分，重组/结合/次单位疫苗凭藉其高效性、长期保护作用和可扩展的生产工艺，在2024年占市场主导地位。灭活疫苗凭藉其安全性和对免疫功能低下患者的适用性，占第二大市场。

依给药途径划分，注射剂疫苗在2024年占市场主导地位。这是因为大多数细菌疫苗都是注射剂，能够快速产生免疫反应。由于口服疫苗给药方便且成本优势明显，预计其成长速度将更快。

依年龄组别划分，受出生率上升和儿童疫苗接种计划扩大的推动，儿童疫苗在2024年占最大占有率。由于成人细菌感染的盛行率不断上升，成人疫苗也持续占较大占有率。

依适应症划分，肺炎链球菌感染疫苗在2024年占市场主导地位，这得益于强有力的疫苗接种建议和日益加重的疾病负担。白喉-破伤风-百日咳疫苗也对市场成长做出了显着贡献。

依分销管道划分，并受联合国儿童基金会和全球疫苗免疫联盟等组织的大规模采购和疫苗接种活动的支持，政府供应商在2024年占市场主导地位。

区域展望

预计北美地区在2025年将创造165.5亿美元的收入，这得益于强有力的疫苗接种计划和高额的医疗保健支出。

欧洲地区预计将保持稳定成长，这得益于其集中采购体系和较高的疫苗接种覆盖率。

亚太地区是成长最快的地区，这主要得益于庞大的人口基数、政府的疫苗接种计划以及印度和中国等国家强大的疫苗生产能力。

拉丁美洲以及中东和非洲地区预计将保持稳定成长，这得益于国际资金的增加以及耐热疫苗和口服疫苗的普及。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家/地区主要疾病的发生率/盛行率（2025 年）
  • 主要公司产品线分析
  • 细菌疫苗的技术进步
  • 主要公司新产品发布
  • 关键产业趋势：併购、业务合作等等。

第五章 全球细菌疫苗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依类型划分
    • 重组/结合/次单位疫苗
    • 灭活​​疫苗
    • 减毒活疫苗
    • 类毒素疫苗
    • 其他
  • 市场分析、洞察与预测：依给药途径划分
    • 注射剂
    • 口服
  • 市场分析、洞察与预测：依年龄组别划分
    • 儿童
    • 成人
  • 市场分析、洞察与预测：依适应症划分
    • 脑膜炎双球菌感染
    • 肺炎链球菌感染
    • 白喉、破伤风和百日咳 (DTP)
    • 其他
  • 市场分析、洞察与预测：依分销管道划分
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美细菌疫苗市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲市场分析细菌疫苗市场：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区细菌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲细菌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东与非洲细菌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC) 国家
    • 南非
    • 其他中东和非洲国家

第十一章：竞争分析

  • 全球市占率分析（2025）
  • 公司简介
    • Sanofi
    • GSK plc.
    • Merck &Co., Inc.
    • Bharat Biotech
    • Pfizer Inc.
    • Emergent BioSolutions, Inc.
    • Serum Institute of india Pvt. Ltd.
    • BIO-MED
Product Code: FBI113652

Growth Factors of bacterial vaccines Market

The global bacterial vaccines market is witnessing robust growth, supported by the rising incidence of bacterial infections, increasing immunization programs, and strong government support across regions. According to Fortune Business Insights, the global bacterial vaccines market was valued at USD 29.68 billion in 2025. The market is projected to reach USD 32.52 billion in 2026 and further expand to USD 81.35 billion by 2034, registering a CAGR of 12.14% during the forecast period. In 2025, North America dominated the market with a share of 40.97%, driven by high vaccine adoption rates and advanced healthcare infrastructure.

Bacterial vaccines are designed to protect individuals against bacterial infections by stimulating the immune system to recognize and neutralize bacterial pathogens. These vaccines play a critical role in preventing life-threatening diseases such as pneumococcal disease, meningococcal disease, diphtheria, tetanus, and pertussis. Rising awareness regarding preventive healthcare and vaccination benefits continues to accelerate global demand for bacterial vaccines.

Market Dynamics

Market Drivers

The growing incidence of bacterial diseases worldwide is a major driver of market growth. Rapid urbanization, increased population density, global travel, and migration have contributed to the spread of bacterial infections, increasing the need for effective immunization strategies. In addition, rising public awareness regarding disease prevention and expanding national immunization programs have significantly increased vaccine uptake, supporting market expansion.

Market Restraints

Regulatory hurdles present a notable restraint in the bacterial vaccines market. Vaccine development involves lengthy clinical trials, strict regulatory compliance, and high capital investment, often extending development timelines up to 10-15 years. Variations in regulatory requirements across countries further complicate global approvals and commercialization, limiting the pace of market growth.

Market Opportunities

The growing threat of antimicrobial resistance (AMR) presents a major opportunity for the bacterial vaccines market. Vaccination reduces reliance on antibiotics, thereby helping to control the emergence of drug-resistant bacterial strains. As antibiotic resistance continues to rise globally, bacterial vaccines are increasingly recognized as a preventive solution, encouraging higher investments and funding support for vaccine development.

Market Challenges

The biological complexity of bacteria poses a significant challenge for vaccine development. Unlike viruses, bacteria possess diverse antigens, making it difficult to identify targets that can generate long-lasting and protective immune responses. This complexity increases research costs and development risks, potentially limiting market growth.

Bacterial Vaccines Market Trends

A prominent trend shaping the market is the development of thermostable bacterial vaccines. These vaccines remain stable across a wide temperature range, reducing dependence on cold-chain logistics. Thermostable vaccines offer a cost-effective and practical solution, especially for emerging economies with limited infrastructure. Increasing R&D investments and ongoing clinical trials for fridge-free vaccines are expected to strengthen this trend during the forecast period.

Segmentation Analysis

By type, the recombinant/conjugate/subunit segment dominated the market in 2024, driven by its high efficacy, long-term protection, and scalable manufacturing processes. The inactivated vaccines segment held the second-largest share, supported by their safety profile and suitability for immunocompromised individuals.

By route of administration, the parenteral segment led the market in 2024, as most bacterial vaccines are injectable and provide rapid immune responses. The oral segment is expected to grow at a faster pace due to ease of administration and cost advantages.

By age group, the pediatric segment accounted for the largest share in 2024, driven by rising birth rates and expanded childhood immunization programs. The adult segment also maintained a substantial share due to increasing prevalence of bacterial infections among adults.

By indication, the pneumococcal disease segment dominated the market in 2024, supported by strong vaccination recommendations and rising disease burden. Diphtheria, tetanus, and pertussis vaccines also contributed significantly to market growth.

By distribution channel, government suppliers dominated the market in 2024, supported by large-scale procurement and vaccination campaigns led by organizations such as UNICEF and GAVI.

Regional Outlook

North America generated USD 16.55 billion in revenue in 2025, supported by strong vaccination programs and high healthcare spending.

Europe is expected to witness steady growth due to centralized procurement systems and high immunization coverage.

Asia Pacific is the fastest-growing region, driven by large population bases, government immunization initiatives, and strong vaccine manufacturing capabilities in countries such as India and China.

Latin America and the Middle East & Africa are projected to grow steadily, supported by increasing international funding and adoption of thermostable and oral vaccines.

Competitive Landscape

The bacterial vaccines market is highly consolidated, with Sanofi, GSK plc., and Merck & Co., Inc. holding a significant share. These companies focus on strong R&D pipelines, global manufacturing capabilities, and strategic collaborations. Other notable players include Bharat Biotech, Pfizer Inc., Emergent BioSolutions, and Serum Institute of India, which continue to expand their product portfolios to strengthen market presence.

Conclusion

The global bacterial vaccines market is set for substantial growth during the forecast period, driven by increasing bacterial disease burden, rising immunization coverage, and growing awareness of preventive healthcare. With the market valued at USD 29.68 billion in 2025, projected to reach USD 32.52 billion in 2026 and expand to USD 81.35 billion by 2034, continuous advancements in vaccine technology, including thermostable formulations and expanded pediatric immunization programs, are expected to shape the future landscape. Despite challenges related to regulatory complexity and bacterial diversity, sustained government support and innovation-driven strategies are anticipated to support long-term market expansion.

Segmentation By Type

  • Recombinant/Conjugate/Subunit
  • Inactivated
  • Live Attenuated
  • Toxoid
  • Others

By Route of Administration

  • Parenteral
  • Oral

By Age Group

  • Pediatrics
  • Adults

By Indication

  • Meningococcal Disease
  • Pneumococcal Disease
  • Diphtheria/Tetanus/Pertussis
  • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Geography

  • North America (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of the Asia Pacific
  • Latin America (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Technological Advancements in the Bacterial Vaccines
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Recombinant/Conjugate/Subunit
    • 5.1.2. Inactivated
    • 5.1.3. Live Attenuated
    • 5.1.4. Toxoid
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Parenteral
    • 5.2.2. Oral
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatrics
    • 5.3.2. Adolts
  • 5.4. Market Analysis, Insights and Forecast - By Indication
    • 5.4.1. Meningococcal Disease
    • 5.4.2. Pneumococcal Disease
    • 5.4.3. Diphtheria/Tetanus/Pertussis
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital & Retail Pharmacies
    • 5.5.2. Government Suppliers
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Recombinant/Conjugate/Subunit
    • 6.1.2. Inactivated
    • 6.1.3. Live Attenuated
    • 6.1.4. Toxoid
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Parenteral
    • 6.2.2. Oral
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatrics
    • 6.3.2. Adolts
  • 6.4. Market Analysis, Insights and Forecast - By Indication
    • 6.4.1. Meningococcal Disease
    • 6.4.2. Pneumococcal Disease
    • 6.4.3. Diphtheria/Tetanus/Pertussis
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital & Retail Pharmacies
    • 6.5.2. Government Suppliers
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Recombinant/Conjugate/Subunit
    • 7.1.2. Inactivated
    • 7.1.3. Live Attenuated
    • 7.1.4. Toxoid
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Parenteral
    • 7.2.2. Oral
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatrics
    • 7.3.2. Adolts
  • 7.4. Market Analysis, Insights and Forecast - By Indication
    • 7.4.1. Meningococcal Disease
    • 7.4.2. Pneumococcal Disease
    • 7.4.3. Diphtheria/Tetanus/Pertussis
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital & Retail Pharmacies
    • 7.5.2. Government Suppliers
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Spain
    • 7.6.5. Italy
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Recombinant/Conjugate/Subunit
    • 8.1.2. Inactivated
    • 8.1.3. Live Attenuated
    • 8.1.4. Toxoid
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Parenteral
    • 8.2.2. Oral
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatrics
    • 8.3.2. Adolts
  • 8.4. Market Analysis, Insights and Forecast - By Indication
    • 8.4.1. Meningococcal Disease
    • 8.4.2. Pneumococcal Disease
    • 8.4.3. Diphtheria/Tetanus/Pertussis
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital & Retail Pharmacies
    • 8.5.2. Government Suppliers
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Recombinant/Conjugate/Subunit
    • 9.1.2. Inactivated
    • 9.1.3. Live Attenuated
    • 9.1.4. Toxoid
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Parenteral
    • 9.2.2. Oral
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatrics
    • 9.3.2. Adolts
  • 9.4. Market Analysis, Insights and Forecast - By Indication
    • 9.4.1. Meningococcal Disease
    • 9.4.2. Pneumococcal Disease
    • 9.4.3. Diphtheria/Tetanus/Pertussis
    • 9.4.4. Others
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital & Retail Pharmacies
    • 9.5.2. Government Suppliers
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Recombinant/Conjugate/Subunit
    • 10.1.2. Inactivated
    • 10.1.3. Live Attenuated
    • 10.1.4. Toxoid
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Parenteral
    • 10.2.2. Oral
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatrics
    • 10.3.2. Adolts
  • 10.4. Market Analysis, Insights and Forecast - By Indication
    • 10.4.1. Meningococcal Disease
    • 10.4.2. Pneumococcal Disease
    • 10.4.3. Diphtheria/Tetanus/Pertussis
    • 10.4.4. Others
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital & Retail Pharmacies
    • 10.5.2. Government Suppliers
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Sanofi
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. GSK plc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Bharat Biotech
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Pfizer Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Emergent BioSolutions, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Serum Institute of india Pvt. Ltd.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. BIO-MED
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 4: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 5: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 8: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 10: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 11: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 16: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 17: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 19: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 20: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 21: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 22: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 23: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 26: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 27: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 28: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 29: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 32: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 33: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 34: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 35: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Bacterial Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Bacterial Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Bacterial Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Bacterial Vaccines Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global Bacterial Vaccines Market Value Share (%), by Indication, 2025 & 2034
  • Figure 6: Global Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Bacterial Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 8: North America Bacterial Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 9: North America Bacterial Vaccines Market Value Share (%), by Type, 2025
  • Figure 10: North America Bacterial Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 11: North America Bacterial Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 12: North America Bacterial Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 13: North America Bacterial Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 14: North America Bacterial Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 15: North America Bacterial Vaccines Market Value Share (%), by Indication, 2025
  • Figure 16: North America Bacterial Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Bacterial Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America Bacterial Vaccines Market Value Share (%), By Country, 2025
  • Figure 20: Europe Bacterial Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 21: Europe Bacterial Vaccines Market Value Share (%), by Type, 2025
  • Figure 22: Europe Bacterial Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 23: Europe Bacterial Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 24: Europe Bacterial Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 25: Europe Bacterial Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 26: Europe Bacterial Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 27: Europe Bacterial Vaccines Market Value Share (%), by Indication, 2025
  • Figure 28: Europe Bacterial Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Bacterial Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Bacterial Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Bacterial Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 33: Asia Pacific Bacterial Vaccines Market Value Share (%), by Type, 2025
  • Figure 34: Asia Pacific Bacterial Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 35: Asia Pacific Bacterial Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 36: Asia Pacific Bacterial Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 37: Asia Pacific Bacterial Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 38: Asia Pacific Bacterial Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 39: Asia Pacific Bacterial Vaccines Market Value Share (%), by Indication, 2025
  • Figure 40: Asia Pacific Bacterial Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Bacterial Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Bacterial Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Bacterial Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 45: Latin America Bacterial Vaccines Market Value Share (%), by Type, 2025
  • Figure 46: Latin America Bacterial Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 47: Latin America Bacterial Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 48: Latin America Bacterial Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 49: Latin America Bacterial Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 50: Latin America Bacterial Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 51: Latin America Bacterial Vaccines Market Value Share (%), by Indication, 2025
  • Figure 52: Latin America Bacterial Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Bacterial Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Bacterial Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Bacterial Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 57: Middle East & Africa Bacterial Vaccines Market Value Share (%), by Type, 2025
  • Figure 58: Middle East & Africa Bacterial Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 59: Middle East & Africa Bacterial Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 60: Middle East & Africa Bacterial Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 61: Middle East & Africa Bacterial Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 62: Middle East & Africa Bacterial Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 63: Middle East & Africa Bacterial Vaccines Market Value Share (%), by Indication, 2025
  • Figure 64: Middle East & Africa Bacterial Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Bacterial Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Bacterial Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Bacterial Vaccines Market Share (%), By Company, 2025